Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Ruchi Gupta

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly and Company (LLY) is a premier global pharmaceutical leader specializing in developing breakthrough therapies across neuroscience, oncology, immunology, and cardiometabolic health. Today, Lilly is at the forefront of a medical revolution, driven by its leadership in incretin-based medicines for Type 2 diabetes and obesity, such as Mounjaro and Zepbound. Beyond metabolic health, the company is advancing high-impact treatments for Alzheimer’s disease and cancer. Eli Lilly is now, with an agreement with Insilico Medicine, expanding that cutting-edge pharmaceutical portfolio into AI-designed drugs.

Headquartered in Indianapolis, Indiana, the company has a legacy spanning 150 years.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.